NeuroVive rights issue 270% oversubscribed NeuroVive

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 31, 2014 at 8:30 AM

NeuroVive rights issue 270% oversubscribed

NeuroVive Pharmaceutical AB (publ) has completed the rights issue approved by an Extraordinary General Meeting on 13 December 2013. The subscription period was 13-27 January 2014. The rights issue was fully subscribed, raising approximately SEK 75.8 m for NeuroVive before issue expenses. Additionally, the Board of Directors has decided to fully exercise its overallocation option of a maximum of 714,286 shares, raising a further SEK 10 m for the company. The rights issue was 90.0% subscribed with subscription rights, and the remainder, 10.0%, without subscription rights. Total applications to subscribe without subscription rights were 270% of the issue, so total applications to subscribe for the issue were 360%. This meant that underwriting guarantees do not need to be utilized. As a result of the oversubscription, the Board has decided to fully utilize its overallocation option, implying another 714,286 shares will be issued. The rights issue raises approximately 75.8 m for the Company, and the overallocation option an additional SEK 10.0 m. This means that NeuroVive will raise a total of some SEK 85.8 m before issue expenses. Allotment of shares subscribed without subscription rights in the rights issue has been conducted in accordance with the principles stated in the prospectus of 8 January 2014. Additionally, the allotment of shares subscribed using the overallocation option has been to existing shareholders in accordance with the aforementioned principles, and to new shareholders who registered their interest in subscribing for shares in the rights issue. This means NeuroVive has increased the number of shareholders by some 500, which is expected to benefit its ownership structure and promote share liquidity. Notice of allotment will be by settlement note to the parties that have been alloted shares. The shares must be paid-up by no later than the date indicated on the settlement note. The new issues (including the over-allocation option) increase NeuroVive’s share capital by SEK 306,452.35 through the issuance of 6,129,047 shares. After the new issue, the number of shares in the company is 27,788,093. The share capital after the new issue is SEK 1,389,404.65. Fully paid-up shares (BTAs) in the rights issue will trade on NASDAQ OMX under the ticker symbol NVP BTA until the issue has been registered with the Swedish Companies Registration Office, and will then be replaced by shares. This is scheduled for the second half of February 2014. On registration, the new shares will be traded on NASDAQ OMX. Subscribers who have been allotted shares under the overallocation option will receive BTAs of another class to those subscribed under the rights issue, which will trade under a different ticker symbol. BTAs received through the overallocation option will be traded on Nasdaq OMX under the ticker symbol NVP BTA 2 and will also be replaced by shares when the issue is registered with the Swedish Companies Registration Office, scheduled at the same time as stated above, i.e. in the second half of February 2014. The new shares will then trade on NASDAQ OMX. Please note that subscribers allotted shares under both the rights issue, NVP BTA, and the overallocation option, NVP BTA 2, will receive two separate settlement notes. After the issues have been registered, all BTAs will be replaced by shares, and these shares will be of the same class. About NeuroVive NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden. For Investor Relations and media questions, please contact: Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or ir@neurovive.se It is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård via the contact above. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48, www.neurovive.se NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 31 January 2014, at 14:00 CET.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Group 1 Automotive Q3 2026: Profits Soar, Revenues Dip

Profits Up, Revenues Down Here's a tale for the books—Group 1 Automotive reports their third quarter results of 2026 and it's a bit like swapping a thunderstorm for a hurricane. Net income from continuing operations stomped on last year's figures, clocking in at a hefty $102.9 million compared to a skimpy $13.1 million. But don't let that fool you, their total revenues...

MidCap Financial Faces Scrutiny Amid Ares Capital Merger

MidCap Financial's Merger Sparks Legal Action Nobody expects their investments to end up in a courtroom drama, but here we are. MidCap Financial Investment Corporation (NASDAQ: MFIC) is under the microscope, thanks to attorney Juan Monteverde's M&A Class Action Firm. From their perch in the Empire State Building, Monteverde & Associates, celebrated as a top dog in the ISS...

Endava Faces Class Action: Investors Eye Their Next Move

A Mess That Investors Can't Ignore If you're holding onto Endava plc shares, you've probably felt that gut-punch lately. Yeah, things are getting heated with a class action lawsuit alleging the company played fast and loose with its accounting practices. The complaint's about some shady dealings that may have thrown off investors' perceptions. The Core Allegations This...

Tabañero Spices Up Holidays with $10 Gift Sets

Hot Sauce, Spicy Gifting, and Bold Barbecue When holiday cheer mixes with a dash of heat, you end up with something as electrifying as Tabañero's latest offerings. This Florida-based player is nudging its way into the gift-giving scene with a lineup that's as spicy as it is thoughtful. Frankly, if you're scrambling for stocking stuffers or a memorable Secret Santa...

Heritage Wines Meet Non-Alcoholic Trend: New Deal

Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...

Webull Faces Class Action: Deadline Looms Dec 2026

Sinking Shares: The Webull Saga Unfolds Shady business practices can really make a stock take a nosedive, and that's what's happening with Webull Corporation, trading under NASDAQ:BULL. The alarm bells started ringing when the truth about their operations and ties to China came out. Turns out, what looked like a stable American fintech platform had its roots digging deep...

Valmet's Strategic Moves and Financial Gains Explained

Valmet's Strategic Playbook for Growth Anyone keeping tabs on Valmet's recent parade of press releases knows they're on a darn aggressive growth spurt. Talk about shaking things up with a firm grip on the paper and forest products sector and beyond. Their interim review from January to September 2026 spells it out with strong orders received and a solid increase in...

Veterinary Implants Market to Hit $0.98B by 2031

Veterinary Implants Market: A Growth Tale Something's stirring in the veterinary world, my friend. The Veterinary Implants Devices Market is hitting some serious strides, and we're looking at a valuation touching nearly $0.98 billion by 2031. If you're eyeing the veterinary sector, it's time to sharpen those pencils and take notes on where the trend winds are blowing....

Brinker International Posts Solid Q1 2027 Earnings

Strong Earnings Highlight a Winning Streak Brinker International, folks, has done it again. With the latest release of their first quarter fiscal 2027 results, it’s clear they’ve been hitting the right notes, especially at Chili’s. The numbers don't lie—trust me, I've seen my fair share of earnings calls, and this one's got meat on the bones. Let’s break it...

Tribal Tech Triumph: ILINX Boosts Proposal Efficiency

A New Era for Tribal Operations Well, here's a headline that might've slipped under your radar, but it’s got some serious implications. Over in Olympia, Washington, ImageSource, Inc., the brains behind the ILINX platform, just scored a home run with an automated system for crafting Tribal Indirect Cost Rate Proposals (ICRPs). This ain't just gadget talk; this is a...